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ABSTRACT
Purpose: To compare the efficacy and costs of circumcision versus topical treatment using a prospective pharmacoeco-
nomic protocol.
Materials and Methods: We treated 59 patients (3-10 years of age) randomized into two groups: 29 underwent an 8-week 
course of topical treatment with 0.2% betamethasone-hyaluronidase cream twice a day; and 30 underwent circumcision. 
Topical treatment success was defined as complete exposure of the glans. In cases of treatment failure, circumcision was 
performed and its cost imputed to that of the initial treatment. The pharmacoeconomic aspects were defined according to 
the Brazilian National Public Health System database and the Brazilian Community Pharmacies Index.
Results: The two groups were statistically similar for all clinical parameters evaluated. Topical treatment resulted in com-
plete exposure of the glans in 52% of the patients. Topical treatment was associated with preputial pain and hyperemia. 
However, treatment suspension was unnecessary. Minor complications were observed in 16.6% of the surgical group 
patients. The mean cost per patient was US$ 53.70 and US$ 125.20, respectively, for topical steroid treatment (including 
the costs related to treatment failure) and circumcision. The total costs were US$ 2,825.32 and US$ 3,885.73 for topical 
treatment and circumcision, respectively.
Conclusions: Topical treatment of phimosis can reduce costs by 27.3% in comparison with circumcision. Therefore, topical 
treatment of phimosis should be considered prior to the decision to perform surgery.
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INTRODUCTION
 Circumcision is considered the elective treat-
ment for phimosis in newborn infants and children. 
In the United States, circumcision is the fourth most 
common surgical procedure, performed in 65.3% of 
the male population (1).
 Various factors, such as social norms, cultural 
traditions and religious beliefs, influence the decision 
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of whether or not to perform circumcision. The Ameri-
can Academy of Pediatrics, in one of their most recent 
publications on this subject, stated that there is no abso-
lute medical indication for the routine circumcision of 
newborn infants, and that, despite the potential medical 
benefits and advantages, circumcision also presents dis-
advantages and risks. When truly indicated, the risks and 
benefits should be discussed with parents, who should be 
asked to give written informed consent (2).
76
Circumcision vs. Topical Corticosteroids in Phimosis
 In the 1990s, due to the controversy sur-
rounding the topic of when circumcision is indicated, 
various studies were carried out in order to investi-
gate alternative treatments for phimosis. Consistent 
success rates were achieved with the use of topical 
corticosteroids (3,4).
 Pharmacoeconomic studies help identify, 
calculate and compare the costs and risks of specific 
programs or therapies, as well as their benefits. Such 
studies also help determine which alternatives provide 
the best results and constitute the most practical use of 
the resources invested. Therefore, pharmacoeconom-
ics is a relevant tool in the decision-making process, 
introducing the concept of economic rationality into 
health care systems in order to complement clinical 
decision making (5). There have been few studies on 
the economic impact of circumcision versus topical 
treatment of phimosis. Therefore, we conducted a 
prospective randomized study comparing, from the 
pharmacoeconomic point of view, the implications 
of topical treatment versus those of circumcision in 
cases of phimosis.
MATERIALS AND METHODS
 A prospective randomized study was carried 
out in order to evaluate the clinical response to topical 
treatment of pathologic phimosis, comparing it to that 
of circumcision.
 We included 85 children, from 3 to 10 years of 
age, diagnosed with phimosis. We defined as phimo-
sis, in this age bracket, phimosis type I (no retraction 
of the foreskin) and type II (external urethral meatus 
exposure only), in accordance with the classification 
system devised by Kayaba et al. (6).
 The study was previously approved by the 
Ethics Committee on Research of our University, 
and all parents or guardians were instructed and 
signed the written informed consent before starting 
the study.
 In the clinical group, 42 patients were treated 
with two daily applications of 0.2% betamethasone 
and hyaluronidase cream for 8 weeks. The same 
physician examined all of the patients. Prior to the 
beginning of treatment and in every subsequent con-
sultation, patients were photographed.
 The therapeutic response was considered 
favorable only if the glans was easily and completely 
exposed during the subsequent physical examination, 
without a phimotic ring or balanopreputial adhesions 
(Kayaba type V). The therapeutic response was con-
sidered unfavorable if there was no exposure of the 
glans or there was only partial exposure of the glans 
due to balanopreputial adhesions or a phimotic ring. 
Therefore, the criterion adopted in order to define 
treatment success was the same as the expected 
outcome of circumcision: complete exposure of the 
glans.
 Patients who responded well to the topical 
treatment underwent outpatient follow-up evaluations 
at 2 and 4 months after the end of treatment.
 Patients who did not respond to the topical 
treatment by week 8 or who presented recurrence dur-
ing the follow-up period underwent circumcision.
 Patients in the surgical group were evaluated 
and then referred to undergo circumcision. Patients 
underwent outpatient follow-up evaluations on post-
operative days 15, 30 and 120.
 All surgical procedures were carried out at 
our institution. The anesthesia protocol was general 
inhalation anesthesia with sevoflurane, in conjunction 
with nerve block of the penis.
 In the present study, the pharmacoeconomic 
analysis was of the cost-minimization type. Only the 
costs of the surgical procedure and clinical treatment 
(those directly related to the health care system: medi-
cal care, medications and medical materials) were 
taken into consideration. Indirect costs related to lost 
productivity, as well as intangible costs (those related 
to pain, suffering and impaired quality of life), were 
not calculated.
 The pharmacoeconomic analysis was carried 
out from the perspective of a Public Health Hospital, 
and the resources included in the cost analysis were 
identified through communications with officials of 
the Brazilian United Health Care System (BUHCS). 
The medication costs that were not available in the 
public health system database were determined by 
consulting the Brazilian Community Pharmacies 
Index.
 For patients in the surgical group, the costs 
were calculated separately for each of the follow-
ing aspects: medical visits; anesthetic medications; 
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surgical materials; medical and nursing team; and 
medications for the treatment of adverse effects.
 For patients in the clinical group, the costs 
of the medical visits were calculated separately from 
those of the medications. Since some of the patients in 
the clinical group were eventually referred to surgery, 
those costs were incorporated into the final costs for 
that group (Figure-1).
 Statistical evaluation of data was carried out 
by means of the chi-square test, Fisher’s exact test, 
likelihood ratio test and Student’s t-test. The level 
of significance was set at p ≤ 0.05. For the pharma-
coeconomic evaluation of the groups, we used the 
nonparametric Mann-Whitney test, for which the level 
of significance was also set at p ≤ 0.05.
RESULTS
 Of the 85 children included in the study, 43 
were allocated to the surgical group and 42 were al-
located to the clinical group. From the surgical group, 
13 children were excluded: 1 due to uncooperative-
ness; 2 due to refusal to undergo surgery; and 10 due 
to failure to return for surgery. Coincidentally, 13 
children were also excluded from the clinical group: 
1 due to irregular use of medication; 1 due to being 
clinically diagnosed with balanitis xerotica obliterans; 
1 due to previous use of medication; and 10 due to 
failure to appear for medical visits. The mean age of 
the population in the study was 5.81 years.
 All clinical parameters evaluated were sta-
tistically similar after the comparison between the 
groups (Table-1).
 In the surgical group, the mean surgical time 
was 34.5 min, the mean time to emergence from anes-
thesia was 43 min, and the mean postoperative stay in 
the infirmary was 47.3 min. On postoperative day 15, 
5 patients presented complications of the procedure: 
2 due to infection caused by improper cleaning; and 
3 due to hematomas and scarring on the glans. These 
complications were considered mild and were treated 
Figure 1 – Flowchart of the pharmacoeconomic study design.
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with intensive local care. In the subsequent follow-up 
visits, all of the patients presented penile conditions 
that were considered normal, with proper formation 
of scar tissue.
 In the clinical group, 15 (51.7%) of the 29 
patients presented complete exposure of the glans 
at 2 months after the end of treatment. The topical 
treatment resulted in adverse effects or complica-
tions in 10 patients: 4 patients experienced hyperemia 
and a burning sensation in the foreskin; 4 patients 
experienced a burning sensation in the foreskin; and 
2 patients presented balanopreputial hyperemia. No 
intervention or treatment interruption was necessary 
in any of the cases.
 In the clinical group, patients in whom treat-
ment success was achieved were monitored for 4 
months. Neither loss of exposure of the glans nor 
recurrence was detected.
 Clinical treatment failure occurred in 14 cas-
es, and those patients were referred to circumcision. 
Of those 14 patients, 2 failed to return for surgery. 
For the 12 who underwent surgery, the mean surgical 
time was 31.2 min, the mean time to emergence from 
anesthesia was 30 min, and the mean postoperative 
stay in the infirmary was 60 min.
 Of the 12 clinical group patients undergoing 
circumcision, 4 presented postoperative complica-
tions: 1 due to infection caused by improper cleaning, 
which demanded oral antibiotic treatment and local 
care; 1 due to bleeding and scars on the gland, which 
was treated locally; 1 due to pyogenic granuloma; and 
1 due to an inflammatory process close to urethral 
meatus. All of the clinical group patients presented 
resolution of the complications during the follow-up 
period.
Pharmacoeconomic Analysis
 In the pharmacoeconomic analysis, we evalu-
ated the direct costs related to treatment of the two 
groups. It is of note that, as previously mentioned, the 
costs related to circumcision of patients in the clinical 
group were included in the final costs for that group 
(Figures 2-3).
 In the pharmacoeconomic evaluation, the 
costs were higher in the clinical group only in terms 
of the medical visits and the use of topical medication. 
Costs regarding medical and nursing staff, anesthetic 
medications and surgical materials were higher in the 
Table 1 – Distribution of clinical findings regarding the incidence of balanitis, exposure of the urethral meatus and excess 
foreskin.
Variable Surgical Clinical p Value Test
Balanitis 0.9 Chi-square test
No 22 73.3% 21 72.4%
Yes   8 26.7%   8 27.6%
Variable Surgical Clinical p Value Test
Visible meatus 0.205 Chi-square test
No 13 43.3% 19 65.5%
Yes 17 56.7% 10 34.5%
Variable Surgical Clinical p Value Test
Excess foreskin 1.000 Fisher’s exact test
No   3 10%   2 7%
Yes 27 90% 27 93%
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surgical group than in the clinical group (p < 0.001). 
No statistical difference was found in costs regarding 
medications used for the treatment of postoperative 
complications.
 As can be seen in Figure-4, the analysis of 
the total costs per group, revealed greater economy 
in the clinical group than in the surgical group US$ 
2,825.32 vs. US$ 3,885.73; p = 0.068; median, US$ 
53.70 vs. US$ 125.20.
 Comparing the median cost to the set price 
stipulated by the BUHCS through the Authorized 
Hospital Admissions System (US$ 52.20) for ev-
ery patient who underwent circumcision, we found 
considerable discrepancy between the amount paid 
by the BUHCS and the actual hospital costs of the 
circumcisions (Figure-5).
COMMENTS
 Circumcision is classically considered the 
gold standard for the treatment of phimosis. Ap-
proximately one-sixth of males worldwide are cir-
cumcised (7). The indications for performing neonatal 
circumcision are controversial. Prominent among the 
factors favoring neonatal circumcision are the lower 
incidence of penile cancer, the lower incidence of 
balanitis/urinary infections, and the prevention of 
sexually transmitted diseases, including AIDS (8,9). 
In addition, the incidence of postoperative complica-
tions is low. These benefits are sufficiently relevant to 
guarantee the routine practice of neonatal circumci-
sion (8). However, most studies in which routine cir-
cumcision is recommended are retrospective studies, 
Figure 2 – Box plot of the cost analysis of the parameters investigated in both groups.
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and the validity of the conclusions should be critically 
investigated. Circumcision is, arguably, a preventive 
health care measure, which, in theory, facilitates 
hygiene. However, the potential benefits occur years 
after the surgery, and few studies involve adequate, 
timely follow-up evaluation (10).
 In Brazil, we do not adopt the concept of neo-
natal circumcision and most indications for surgery 
are considered when the child is about to leave diapers 
and only patients with phimotic ring are candidates 
for this kind of treatment.
 The clinical treatment of phimosis consists of 
the gentle retraction of the foreskin and application of a 
topical corticosteroid to the foreskin and phimotic ring, 
with the objective of achieving complete exposure of the 
glans. The effects of topical corticosteroids, which have 
anti-inflammatory and immunosuppressive properties, 
on the metabolism of arachidonic acid and inhibition 
of interleukin-1 synthesis have been well established. 
Topical corticosteroids can have an antiproliferative ef-
fect on the dermal matrix, decreasing skin thickness and 
obliterating the stratum corneum (11,12).
 Hyaluronidase acts by modifying intercellular 
permeability and reducing tissue resistance, thereby 
increasing the diffusion of substances between planes 
(13).
 In a pioneer study on the application of topical 
corticosteroid in boys with phimosis who were candi-
dates for circumcision, clinical treatment was shown 
to be viable and efficacious (3). Topical treatment 
of phimosis with corticosteroids has characteristics 
that make it quite attractive as the first approach to 
the treatment of phimosis. The method is safe, and 
complication rates are similar to those found for 
circumcision. In addition, corticosteroid treatment 
presents high cure rates and low costs, as well as be-
Figure 3 – Box plot of the cost analysis of the parameters investigated in both groups.
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ing easily administered and being well accepted by 
family members (14-16).
 In the present study, 51.7% of the patients 
in the clinical group presented complete exposure of 
the glans, and none presented recurrence or lack of 
exposure of the glans during the 4 months of post-
treatment follow-up evaluation. It is of note that 
Figure 4 – Box plot of the analysis of total costs in both groups.
we adopted a strict criterion for treatment success, 
excluding partial exposure of the glans, and that, in 
65.5% of the patients, only the urethral meatus was 
exposed (Kayaba type I) prior to treatment. In multi-
variate analyses, Kayaba type I presentation has been 
described as a determining factor for corticosteroid 
treatment success (16).
Figure 5 – Comparison between the value transferred by the Unified Health Care System for the surgical procedure (circumcision) and 
median costs of the clinical and surgical groups. AHA-UHCS = Authorized Hospital Admissions-Unified Health Care System.
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 There have been few studies comparing the 
economic impact of circumcision with that of topical 
treatment in individuals with phimosis. It has been 
estimated that topical treatment reduces costs by 75% 
in comparison with circumcision, representing, for 
example, a potential annual savings of 150 million 
francs in France (17,18). However, in such studies, 
costs and treatment outcomes are estimated based 
on the means obtained in previous studies, and the 
potential economic risks of future complications are 
only speculated upon.
 Van Howe (2004) conducted a cost-utility 
analysis of neonatal circumcision, evaluating the 
impact on the quality of life of patients for 72 years 
after circumcision (19). The author concluded that 
neonatal circumcision is more costly and has more 
adverse effects on the lifetime health of individuals 
than does not undergoing this procedure. Neverthe-
less, in a retrospective study evaluating the costs of 
circumcision, the authors concluded that neonatal 
circumcision provides medical benefit and prevents 
various pathologies, as well as costing ten times less 
than postnatal circumcision (20).
 In general, pharmacoeconomic analysis 
consists of two essential elements: costs and out-
come, which are, respectively, the nominator and 
the denominator of the equation. The pharmaco-
economic analysis in this study was based on cost 
minimization, in which we compared the costs of 
two treatment modalities whose final outcome 
measure was the resolution of pathologic phimosis 
(5).
 The analysis showed that the costs of all items 
related to the clinical treatment were lower than were 
those related to the surgical treatment, except for 
the costs regarding medical visits and use of topical 
medication, which were not used in the surgical group 
patients. The evaluation showed that the clinical 
parameters, age brackets, follow-up rates and non-
compliance rates were similar in the two groups. No 
differences were found between the groups in terms 
of surgical time or incidence of complications.
 The cost savings corresponded to the total 
cost of treating the patients in the surgical group (US$ 
3,885.73) subtracted from the total cost of treating the 
patients in the clinical group (US$ 2,825.32). The cost 
savings, which was the amount of money saved by 
using the topical treatment as the first-line treatment, 
was US$ 1,060.40.
 Finally, when we compared the total costs of 
the treatment with the governmental reference values 
for circumcision, we found that amount provided by the 
health care system does not cover the costs of the surgical 
procedure. Therefore, topical corticosteroid administra-
tion as the first-line treatment for phimosis could represent 
a considerable savings to the institution.
 We acknowledge some criticism of our study 
when considering that only complete exposure of 
the glans without a phimotic ring was defined as 
a favorable result of topic treatment. On the other 
hand, we tried to make the end-point of both kinds 
of treatment comparable and this could justify our 
methodology.
 A second point of concern by some authors 
would be that our results with non-surgical treatment 
were inferior to most other published series that report 
higher (90-95%) rates of efficiency. We stress that at 
the age we proposed to study these patients most boys 
had already experienced spontaneous resolution of 
phimosis, therefore, we were really comparing patients 
in the “waiting list” for surgery at our institution.
CONCLUSIONS
 As a first-line treatment for phimosis, topi-
cal corticosteroid administration reduced costs by 
27.3% in comparison with circumcision, even when 
we included the costs of the circumcisions eventually 
performed in the clinical treatment group. The mean 
cost of circumcision per child was US$ 125.00 and 
for topical treatment was US$ 54.00, so that US$ 
35.00 could have been saved in the Brazilian public 
health system per child if conservative treatment had 
primarily been used.
 These data underscore the concept that topi-
cal treatment should be offered to patients prior to 
considering surgery.
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EDITORIAL COMMENT
 This randomized trial compares the efficacy 
and costs of an 8-week topical treatment with 0.2 be-
tamethasone and hyaluronidase vs. primary circumci-
sion in children with phimosis. The authors concluded 
that topical steroid treatment reduced the costs by 
27.3% in comparison with circumcision. Only a few 
pharmacoeconomic analyses related to the treatment 
of these two groups have been published in the lit-
erature. However, I am skeptical about the definition 
of phimosis according to the Kayaba’s (1) classifica-
tion. What the authors defined as phimosis may well 
represent physiological phimosis. In the physiological 
phimosis, the non-retractile foreskin forms a normal 
and unscarred preputial orifice and when the foreskin 
is retracted, the preputial meatus opens as a flower. 
The appearance of pathological phimosis is clear with 
the preputial orifice white, indurated, and scarred. I am 
wondering whether children were treated because of 
physiological phimosis that would resolve spontane-
ously up to adolescence.
 I must acknowledge the effort of the authors 
in setting this study together. However, there are some 
limitations related to this study. First, because of the 
relatively small number of patients the results of this 
trial may reflect a low statistical power rather than real 
differences between the two methods used. Second, 
we cannot exclude the possibility that another density 
of betamethasone would have different results than 
those observed here. How and why the authors chose 
a 0.2% betamethasone and hyaluronidase cream? 
An additional concern is that, although the authors 
compare a topic steroid to primary circumcision, one 
might question whether steroid is superior to a control 
group. Unless the authors include this group, the study 
may present biased and incomplete information.
REFERENCE
1. Kayaba H, Tamura H, Kitajima S, Fujiwara Y, Kato 
T, Kato T: Analysis of shape and retractability of the 
prepuce in 603 Japanese boys. J Urol. 1996; 156: 
1813-5.
Dr. George Vaos
Department of Pediatric Surgery
Alexandroupolis University Hospital




 Local corticosteroid application has become 
a popular alternative to the surgical treatment for 
phimosis during the last decade. Thus, it is useful 
to compare these treatment modalities also from the 
economical point of view. It was interesting that the 
nonsurgical treatment was more economical despite 
a quite high failure rate in this study. The reported 
success rates of the corticosteroid treatment are very 
variable, perhaps because of the patient selection. It 
is important to distinguish physiologic congenital 
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phimosis and pathological phimosis with scars when 
deciding whether or not to treat. It has been shown 
that the incidence of phimosis is 50% at the age of 
1 year, 8% at the age of 6 years and 1 % at the age 
of 15 years (1). The possible health benefit for treat-
ing physiologic phimosis is controversial. In our 
hospital, physiologic phimosis is treated only in the 
rare cases with significant symptoms e.g. in voiding. 
In non-symptomatic cases, spontaneous resolution 
of phimosis is  delayed until puberty. In pathologic 
phimosis, the prepuce is scarred mostly due to skin 
disease balanitis xerotica obliterans. Usually patho-
logical phimosis is not observed before school age. 
In our hospital, the main indication for circumcision 
is pathological phimosis with scars.  In the present 
series, no patient had pathological phimosis and few 
had symptoms. I find the indications for treatment 
unclear in this study and think that it could have been 
more economical not to treat most of these patients at 
all.
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